Filtering by content type: Public Statement
Filtering by content type: Press Release
The Federal Trade Commission has closed its investigation into the proposed merger of Aveanna Healthcare and Maxim Healthcare.
For 2020, the size-of-transaction threshold for reporting proposed mergers and acquisitions under Section 7A of the Clayton Act will adjust from $90 million to $94 million. Also, the 2020 thresholds under Section 8 of the Act that trigger prohibitions on certain interlocking memberships on...
Following a recent public workshop on non-compete clauses in employer-employee contracts, the Federal Trade Commission has extended the deadline for public comments from Feb. 10, 2020 to March 11, 2020.
The Federal Trade Commission has filed a complaint in federal court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim.
The Federal Trade Commission is currently accepting public comments on an application by Par Petroleum Corp. to modify the Amended Honolulu Terminal Agreement.
“The FTC unanimously voted to challenge this deal because it was likely to lead to higher prices and reduced quality for private label ready-to-eat cereals. Households across America have benefitted from robust competition between Post and TreeHouse, and they will continue to do so now that this...
The Federal Trade Commission has adjusted the maximum civil penalty dollar amounts for violations of 16 provisions of law the FTC enforces, as required by the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015. The Act directs agencies to implement annual inflation...
Federal Trade Commission staff submitted comments to two state legislatures on the impact of legislative proposals to modify the supervision requirements imposed on advanced practice registered nurses, or APRNs.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bristol-Myers Squibb Company’s proposed $74 billion acquisition of Celgene Corporation would violate federal antitrust law.
Filtering by content type: Federal Register Notice
Filtering by content type: Case
The Federal Trade Commission has filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint...